FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:691-697 March 10, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Tomasz, A. PubMed Citation

Hairy-cell Leukemia, or leukemic reticuloendotheliosis, is an uncommon chronic lymphoproliferative disorder first described by Bouroncle et al. in 1958¹. Its defining features are mononuclear cells with prominent cytoplasmic projections (Figure 1) that retain acid phosphatase stain when treated with tartrate, and a typical pattern of cellular infiltration in the bone marrow and spleen^1,2. In the marrow the hairy cells contain abundant pale cytoplasm, giving rise to a "fried egg" appearance, and in the spleen the disruption of normal sinus architecture results in the formation of blood-filled spaces. Immunophenotypic analysis of the circulating hairy cells reveals them . . . [Full Text of this Article]

Rationale for Development

Purine Metabolism in Lymphocytes

Mechanisms of Action of 2'-Deoxycoformycin and 2-Chlorodeoxyadenosine

Results of Clinical Trials

2'-Deoxycoformycin

2-Chlorodeoxyadenosine

Fludarabine

Treatment Considerations

Source Information

From the Division of Hematology-Oncology, Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, La Jolla, Calif.

Address reprint requests to Dr. Saven at the Division of Hematology-Oncology, Scripps Clinic and Research Foundation, 10666 N. Torrey Pines Rd., La Jolla, CA 92037.

References

This article has been cited by other articles:

• Jacobsohn, D. A., Chen, A. R., Zahurak, M., Piantadosi, S., Anders, V., Bolanos-Meade, J., Higman, M., Margolis, J., Kaup, M., Vogelsang, G. B. (2007). Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease. JCO 25: 4255-4261 [Abstract] [Full Text]  
• Robak, T., Jamroziak, K., Gora-Tybor, J., Blonski, J. Z., Kasznicki, M., Dwilewicz-Trojaczek, J., Wiater, E., Zdunczyk, A., Dybowicz, J., Dmoszynska, A., Wojtaszko, M., Zdziarska, B., Calbecka, M., Kostyra, A., Hellmann, A., Lewandowski, K., Stella-Holowiecka, B., Sulek, K., Gawronski, K., Skotnicki, A. B., Nowak, W., Zawilska, K., Molendowicz-Portala, L., Kloczko, J., Sokolowski, J., Warzocha, K., Seferynska, I., Ceglarek, B., Konopka, L., for the Polish Adult Leukemia Group, (2007). Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109: 3672-3675 [Abstract] [Full Text]  
• Bolanos-Meade, J., Jacobsohn, D. A., Margolis, J., Ogden, A., Wientjes, M. G., Byrd, J. C., Lucas, D. M., Anders, V., Phelps, M., Grever, M. R., Vogelsang, G. B. (2005). Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease. JCO 23: 2661-2668 [Abstract] [Full Text]  
• Goodman, G. R., Burian, C., Koziol, J. A., Saven, A. (2003). Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine. JCO 21: 891-896 [Abstract] [Full Text]  
• Saito, T., Kanda, Y., Kami, M., Kato, K., Shoji, N., Kanai, S., Ohnishi, T., Kawano, Y., Nakai, K., Ogasawara, T., Matsubara, H., Makimoto, A., Tanosaki, R., Tobinai, K., Wakasugi, H., Takaue, Y., Mineishi, S. (2002). Therapeutic Potential of a Reduced-Intensity Preparative Regimen for Allogeneic Transplantation with Cladribine, Busulfan, and Antithymocyte Globulin against Advanced/Refractory Acute Leukemia/Lymphoma. Clin. Cancer Res. 8: 1014-1020 [Abstract] [Full Text]  
• Ahmad, I., Al-Katib, A. M., Beck, F. W. J., Mohammad, R. M. (2000). Sequential Treatment of a Resistant Chronic Lymphocytic Leukemia Patient with Bryostatin 1 Followed by 2-Chlorodeoxyadenosine: Case Report. Clin. Cancer Res. 6: 1328-1332 [Abstract] [Full Text]  
• Ghura, H S, Carmichael, A J, Bairstow, D, Finney, R (1999). Drug points: Fatal erythroderma associated with pentostatin. BMJ 319: 549-549 [Full Text]  
• Saven, A., Burian, C. (1999). Cladribine Activity in Adult Langerhans-Cell Histiocytosis. Blood 93: 4125-4130 [Abstract] [Full Text]  
• Saven, A., Burian, C., Adusumalli, J., Koziol, J. A. (1999). Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia. Blood 93: 2471-2477 [Abstract] [Full Text]  
• Saven, A., Burian, C., Koziol, J. A., Piro, L. D. (1998). Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment. Blood 92: 1918-1926 [Abstract] [Full Text]  
• Kluin-Nelemans, H. C., Kester, M. G.D., van deCorput, L., Boor, P. P.C., Landegent, J. E., van Dongen, J. J.M., Willemze, R., Falkenburg, J.H. F. (1998). Correction of Abnormal T-Cell Receptor Repertoire During Interferon-alpha Therapy in Patients With Hairy Cell Leukemia. Blood 91: 4224-4231 [Abstract] [Full Text]  
• Hentosh, P., Tibudan, M. (1997). 2-Chloro-2'-deoxyadenosine, an Antileukemic Drug, Has an Early Effect on Cellular Mitochondrial Function. Mol. Pharmacol. 51: 613-619 [Abstract] [Full Text]  
• Kolesar, J. M., Morris, A. K., Kuhn, J. G. (1996). Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine. J Oncol Pharm Pract 2: 160-181 [Abstract]